132 related articles for article (PubMed ID: 27468779)
21. N-Acetyl-D-glucosamine decorated polymeric nanoparticles for targeted delivery of doxorubicin: Synthesis, characterization and in vitro evaluation.
Tian B; Ding Y; Han J; Zhang J; Han Y; Han J
Colloids Surf B Biointerfaces; 2015 Jun; 130():246-54. PubMed ID: 25921641
[TBL] [Abstract][Full Text] [Related]
22. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G
Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541
[TBL] [Abstract][Full Text] [Related]
23. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
[TBL] [Abstract][Full Text] [Related]
24. Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the β-Particle-Emitter, (177)Lu.
Yook S; Cai Z; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2015 Nov; 12(11):3963-72. PubMed ID: 26402157
[TBL] [Abstract][Full Text] [Related]
25. Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells.
Yu K; Zhao J; Zhang Z; Gao Y; Zhou Y; Teng L; Li Y
Int J Pharm; 2016 Jan; 497(1-2):78-87. PubMed ID: 26617314
[TBL] [Abstract][Full Text] [Related]
26. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
27. Enzyme and Thermal Dual Responsive Amphiphilic Polymer Core-Shell Nanoparticle for Doxorubicin Delivery to Cancer Cells.
Kashyap S; Singh N; Surnar B; Jayakannan M
Biomacromolecules; 2016 Jan; 17(1):384-98. PubMed ID: 26652038
[TBL] [Abstract][Full Text] [Related]
28. Enhanced Human Epidermal Growth Factor Receptor 2 Degradation in Breast Cancer Cells by Lysosome-Targeting Gold Nanoconstructs.
Lee H; Dam DH; Ha JW; Yue J; Odom TW
ACS Nano; 2015 Oct; 9(10):9859-67. PubMed ID: 26335372
[TBL] [Abstract][Full Text] [Related]
29. Synthetic NRG-1 functionalized DNA nanospindels towards HER2/neu targets for in vitro anti-cancer activity assessment against breast cancer MCF-7 cells.
Baig MMFA; Lai WF; Mikrani R; Jabeen M; Naveed M; Abbas M; Farooq MA; Ahsan A; Kassim SA; Khan GJ; Ansari MT
J Pharm Biomed Anal; 2020 Apr; 182():113133. PubMed ID: 32004770
[TBL] [Abstract][Full Text] [Related]
30. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
[TBL] [Abstract][Full Text] [Related]
31. Tumour-Targeted Drug Delivery with Mannose-Functionalized Nanoparticles Self-Assembled from Amphiphilic β-Cyclodextrins.
Ye Z; Zhang Q; Wang S; Bharate P; Varela-Aramburu S; Lu M; Seeberger PH; Yin J
Chemistry; 2016 Oct; 22(43):15216-15221. PubMed ID: 27714939
[TBL] [Abstract][Full Text] [Related]
32. Differential response to doxorubicin in breast cancer subtypes simulated by a microfluidic tumor model.
Ozcelikkale A; Shin K; Noe-Kim V; Elzey BD; Dong Z; Zhang JT; Kim K; Kwon IC; Park K; Han B
J Control Release; 2017 Nov; 266():129-139. PubMed ID: 28939108
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of cellular and transcriptional targeting of breast cancer stem cells via anti-HER2 nanobody conjugated PAMAM dendrimers.
Reshadmanesh A; Rahbarizadeh F; Ahmadvand D; Jafari Iri Sofla F
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S105-S115. PubMed ID: 30246563
[TBL] [Abstract][Full Text] [Related]
34. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles.
Anhorn MG; Wagner S; Kreuter J; Langer K; von Briesen H
Bioconjug Chem; 2008 Dec; 19(12):2321-31. PubMed ID: 18937508
[TBL] [Abstract][Full Text] [Related]
35. AS1411 aptamer and folic acid functionalized pH-responsive ATRP fabricated pPEGMA-PCL-pPEGMA polymeric nanoparticles for targeted drug delivery in cancer therapy.
Lale SV; R G A; Aravind A; Kumar DS; Koul V
Biomacromolecules; 2014 May; 15(5):1737-52. PubMed ID: 24689987
[TBL] [Abstract][Full Text] [Related]
36. A specific peptide ligand-modified lipid nanoparticle carrier for the inhibition of tumor metastasis growth.
Wang Z; Yu Y; Dai W; Cui J; Wu H; Yuan L; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Biomaterials; 2013 Jan; 34(3):756-64. PubMed ID: 23117217
[TBL] [Abstract][Full Text] [Related]
37. Nano-pharmaceutical formulations for targeted drug delivery against HER2 in breast cancer.
Sadat SM; Saeidnia S; Nazarali AJ; Haddadi A
Curr Cancer Drug Targets; 2015; 15(1):71-86. PubMed ID: 25564255
[TBL] [Abstract][Full Text] [Related]
38. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug.
Jain A; Agarwal A; Majumder S; Lariya N; Khaya A; Agrawal H; Majumdar S; Agrawal GP
J Control Release; 2010 Dec; 148(3):359-67. PubMed ID: 20854859
[TBL] [Abstract][Full Text] [Related]
39. Bile acid-conjugated chondroitin sulfate A-based nanoparticles for tumor-targeted anticancer drug delivery.
Lee JY; Chung SJ; Cho HJ; Kim DD
Eur J Pharm Biopharm; 2015 Aug; 94():532-41. PubMed ID: 26149228
[TBL] [Abstract][Full Text] [Related]
40. Polyglutamic Acid-Gated Mesoporous Silica Nanoparticles for Enzyme-Controlled Drug Delivery.
Tukappa A; Ultimo A; de la Torre C; Pardo T; Sancenón F; Martínez-Máñez R
Langmuir; 2016 Aug; 32(33):8507-15. PubMed ID: 27468799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
